Key Takeaways
- Sharp sequential recovery, but war caps ambition: Revenue rebounded 20% QoQ in Q4 FY26, yet the West Asia conflict forced the FY27 EBITDA margin target down to 13.5–14% from an earlier 14–14.5% aspiration.
- Backward integration is the margin story: The methylamine plant is the only indigenous metformin intermediate facility, and its ramp-up toward 70% utilization is the single biggest lever for self-sufficiency and operating leverage.
- Salicylic acid remains a deliberate drag: Production was shut to stop variable losses; restart hinges on phenol-recovery equipment, an effluent solution with the government, and a delayed derivatives plant, making the timeline a chain of dependencies.
- Regulated-market pivot is underway but early: Exports rose to 38% of revenue and regulated markets to 73%, yet material US and European API flows from the reapproved plant are still 12–18 months out.
- What to watch next quarter: Whether the Sayakha plant hits real profitability within the promised 3–4 months, the pace of methylamine utilization past 60%, and any salicylic acid restart signal.
Methylamine Plant & Metformin Backward Integration
- Utilization trajectory: The plant fell short of a 45–50% target because of ammonia-based raw material shortages from the West Asia war; it is expected to cross 55–60% in the June quarter and operate above 70% within a year.
- Competitive moat: Aarti Drugs is now the only player with backward integration for the indigenous intermediate of metformin, making it very cost-competitive in rest-of-world markets.
- Regulatory catalyst: A DMF has been filed with the US FDA; once capacity ramps up, the company will invite an FDA inspection, and US approval is key even for selling into European markets.
- Margin linkage: Reduced dependence on externally sourced inputs for the metformin portfolio supports both margin improvement and operating leverage as utilization scales.
Adhish Patil: "I believe now we are the only ones as of today with a backward integration facility. So, that puts us in a very good position."
Salicylic Acid: Shutdown, Restart Conditions & Forward Integration
- Production halted: The company shut salicylic acid production because variable losses were being incurred; it could not recover or reduce raw material cost without a specific piece of equipment.
- Restart chain: Three conditions must align: phenol-recovery equipment installation (pilot batches done, delivery expected late April), an effluent-treatment solution for high-saline water (under discussion with the government), and the antidumping duty application that is ongoing.
- Derivatives plant delayed: The forward-integration plant is commissioned but delayed to end of May or mid-June due to a severe fabrication labor shortage in summer, partly linked to lack of cooking gas.
- No point rushing: Management is explicit that higher production without the phenol-recovery equipment would cause more losses, so the restart waits on that installation.
Adhish Patil: "Unless we install that equipment, there is no point in going ahead with higher production of salicylic acid because then that will, in turn, cause more losses for us."
Sayakha Plant Ramp-Up
- Utilization jump: Improved from ~30% in the December quarter to over 40% in March despite raw material shortages, and the first half of Q1 FY27 is already at ~60%.
- Minor hiccup: A small internal issue at the drying stage of one methylamine derivative was flagged but is not a concern.
- Profitability timeline: Real profitability is expected to start showing results within 3–4 months; better utilization depends on metformin expansion plans.
- Capex enabler: If cash flow from Sayakha and salicylic acid improves starkly, the INR300–400 crore capex plan over two to three years could be higher.
Regulated-Market & Formulation Push
- Structural shift: Export share moved from 35% to 38% of revenue, and regulated-market contribution from 66% to 73%, signaling ability to meet stringent norms.
- US FDA plant: Received plant approval for APIs last year; the company is actively marketing antibiotic, anti-inflammatory and other therapy products, with flows expected to start within 12–18 months.
- European approvals: CEPs taken for antifungal and anti-inflammatory products in dedicated plants.
- Formulation growth: A INR90 crore quarterly run rate is possible to maintain in FY27, with a target to reach at least INR1,000 crores in the next three to five years; an additional OSD block will double non-oncology capacity and be made EDQM-compliant.
- Oncology still pre-revenue: Dossiers are in the approval stage; development requires heavy capex, and part of CWIP relates to oncology dossiers.
Margins, Costs & the War Overhang
- Gross margin stability: Q4 gross margins were fairly good; management wants to maintain that level and sees ~1% of manufacturing cost reduction as achievable to improve EBITDA margin.
- The war tax on targets: The earlier FY27 EBITDA margin target of 14–14.5% was cut to 13.5–14% explicitly because of the West Asia war, which drove elevated input costs, freight, packaging, utility and energy costs, plus inconsistent raw material availability.
- Crude sensitivity: If crude stays above $110–$120 per barrel, older-generation antibiotic molecules sold cheaply in the Indian market may see demand decline, as observed during the Russia-Ukraine war in 2023.
- API pricing stable for now: Prices have stabilized and no further increases are expected unless crude goes beyond $130–$140 per barrel.
- New-project drag: The total EBITDA loss from new projects in FY26 was roughly INR18–20 crores, per an analyst's math confirmed by management.
Adhish Patil: "Had this war not been there, our earlier targets were definitely 14% to 14.5% EBITDA margin for FY 2027."
Volume, Pricing & Demand Outlook
- Volume growth track record: Aarti Drugs has delivered positive volume growth over the last five years despite sharp pricing corrections; the internal target is 10–15% growth, with 8–10% seen as fairly easy given built-up capacities from two greenfield expansions.
- Pricing stabilization: Pricing trends started stabilizing from September 2025, and the recovery strengthened further during Q4 FY26 supported by increasing crude prices.
- Antibiotic segment: Sequential recovery in March versus December; expecting very big price growth YoY in FY27, though volumes are likely flattish after a weak FY26.
- Realization tailwind: Realizations are expected to be positive, and the longer the West Asia war stretches, the more positive the variance.
- Raw material watch: The only recent availability issue was an ammonia shortage in March; otherwise no crunch as of now.
Adhish Patil: "If the crude prices remain elevated very high, then the older generation molecules, which are already being sold at a very cheaper rate in the Indian market, and there is some kind of price regulation for the formulation players... when the API become very expensive, typically, the demand of those products goes down."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Methylamine plant utilization | Cross 55–60%, then operate above 70% | June quarter / within a year |
| Sayakha plant profitability | Real profitability to start showing results | Within 3–4 months |
| EBITDA margin | 13.5% to 14% | FY27 |
| US API flows from reapproved plant | Flows to start for antibiotic, anti-inflammatory and other therapies | Within 12–18 months |
| Formulation quarterly run rate | INR90 crores maintained | FY27 |
| Formulation revenue target | At least INR1,000 crores | Next 3–5 years |
| Capex | INR300–400 crores; could be higher if Sayakha and salicylic acid cash flow improves starkly | Next 2–3 years |
| CWIP amortization (formulation) | Most starts amortizing; major chunk post 24 months | Over next 24 months |
| Salicylic acid derivatives plant | Commissioned and operational | End of May / mid-June |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹721.1 cr, +6% YoY and +20% QoQ |
| Consolidated EBITDA | ₹96.6 cr, flattish YoY and +72% QoQ |
| EBITDA margin | 13.4% |
| Consolidated PAT | ₹55.3 cr, -12% YoY and +36% QoQ |
| PAT margin | 7.7% |
| Standalone revenue | ₹631.7 cr, vs ₹623.0 cr in Q4 FY25 |
| Standalone domestic revenue growth | +7% YoY |
| Standalone export revenue growth | -7% YoY |
| Formulation revenue | ₹91.3 cr, +41% YoY; exports contributed 69% |
| FY26 formulation revenue | ₹330.5 cr, +16% YoY; exports contributed 65% |
| API antibiotic share of API sales | 37.8% |
| API anti-protozoal share of API sales | 19.6% |
| API anti-inflammatory share of API sales | 11.9% |
| API antidiabetic share of API sales | 15.0% |
| API anti-fungal share of API sales | 10.0% |
| Exports contribution to consolidated revenue | 38% in FY26, up from 35% in FY25 |
| Regulated market share of exports | 73% in FY26, up from 66% in FY25 |
| Methylamine plant production rate | ~1,000 tonnes per month in March 2026 |
| Methylamine plant utilization | ~40% in Q4 FY26, up from ~29% in Q3 FY26 |
| Methylamine plant utilization target | 55%–60% expected in Q1 FY27, upwards of 70% within a year |
| Formulation business EBITDA margin | 16%–17%, consistent for last two quarters |
| FY27 EBITDA margin target | 13.5%–14.0%; earlier pre-war target was 14.0%–14.5% |
| Capex plan | ₹300 cr–₹400 cr over next two to three years |
| Formulation business revenue target | ₹1,000 cr in next three to five years |
| Consolidated long-term debt | ₹328 cr |
| Consolidated short-term debt | ₹248 cr |
| CWIP | ₹214 cr |
| Total EBITDA loss from new projects in FY26 | ₹18 cr–₹20 cr |